The overlap between IBS and IBD-what is it and what does it mean?

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 2, 2014, Pages 139-145

  Stanisic, Vladimir ^a   Quigley, Eamonn Mm ^a  

^a Division of Gastroenterology and Hepatology   (United States)

Author keywords

calprotectin; cytokines; immune activation; inflammatory bowel disease; irritable bowel syndrome; irritable inflammatory bowel syndrome

Indexed keywords

CALGRANULIN; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1;

ABDOMINAL PAIN; ANXIETY; BLOATING; CROHN DISEASE; DEFECATION HABIT; HUMAN; IMMUNOREACTIVITY; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN EXPRESSION; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; RISK FACTOR; SYMPTOMATOLOGY;

COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PREVALENCE;

EID: 84893120032     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.876361     Document Type: Review

References (42)

1. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73
2. Camilleri M, Katzka DA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;302:1075-84
3. Vivinus-Nebot M, Dainese R, Anty R, et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 2012;107:75-81
4. Pastorelli L, De Salvo C, Mercado JR, et al. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 2013;4:280
5. Van Limbergen J, Russell RK, Nimmo ER, et al. Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:338-55
6. Danese S. Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2011;300:716-22
7. Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012;24:503-12
8. Matricon J, Meleine M, Gelot A, et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012;36:1009-31
9. Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol 2013;11:1075-83
10. Overman EL, Rivier JE, Moeser AJ. CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-Alpha. PLoS ONE 2012;7:e39935
11. Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 2013; [Epub ahead of print] .
12. Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am 2011;40:1-10
13. World Gastroenterology Organization Global Guideline. Irritable bowel syndrome: a global perspective. Available from: www. worldgastroenterology.org
14. CDC. Inflammatory Bowel Disease (IBD). Available from: www.cdc.gov/ibd/#epidIBD
15. Jelsness-Jorgensen LP, Bernklev T, Moum B. Calprotectin Is a useful tool in distinguishing coexisting irritable bowel-like symptoms from that of occult inflammation among inflammatory bowel disease patients in remission. Gastroenterol Res Pract 2013:620707. . Supports the value of calprotectin in detecting activity in IBD and distinguishing it from IBS.
16. Keohane J, OMahony C, OMahony L, et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010;105:1789-94 . Argues the IBS-type symptoms in IBD represents ongoing, albeit, subclinical activity of IBD.
17. Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002;97:389-96
18. Barratt SM, Leeds JS, Robinson K, et al. Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohns disease and celiac disease, but not ulcerative colitis. Dig Dis Sci 2011;56: 3270-5
19. Barratt SM, Leeds JS, Robinson K, et al. Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2010;23:159-65
20. Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther 2013;38:44-51
21. Jelsness-Jorgensen LP, Bernklev T, Moum B. Fatigue and disease-related worries among inflammatory bowel disease patients in remission; is it a reflection of coexisting IBS-like symptoms? A short report. J Psychosom Res 2012;73:469-72
22. Jonefjall B, Strid H, Ohman L, et al. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil 2013;25:756-578 .
23. Aguas M, Garrigues V, Bastida G, et al. Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD). J Crohns Colitis 2011;5:227-33
24. Porter CK, Cash BD, Pimentel M, et al. Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol 2012;12:55
25. Akbar A, Yiangou Y, Facer P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 2010;59: 767-74
26. Keszthelyi D, Jonkers DM, Hamer HM, Masclee AA. Letter: the role of sub-clinical inflammation and TRPV1 in the development of IBS-like symptoms in ulcerative colitis in remission. Aliment Pharmacol Ther 2013;38:560-1
27. Garc?a Rodr?guez LA, Ruigomez A, Wallander MA, et al. Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2000;35:306-11
28. Minderhoud IM, Oldenburg B, Wismeijer JA, et al. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004;49: 469-74
29. Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis-how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006;4:614-20
30. Olbe L. Concept of Crohns disease being conditioned by four main components, and irritable bowel syndrome being an incomplete Crohns disease. Scand J Gastroenterol 2007;3:1-8
31. Macsharry J, OMahony L, Fanning A, et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008;43:1467-76
32. Kiank C, Tache Y, Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun 2009;24: 41-8
33. DHaens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18: 2218-24
34. af Bjorkesten CG, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohns disease. Scand J Gastroenterol 2012;47:528-37
35. Oikonomou KA, Kapsoritakis AN, Theodoridou C, et al
36. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000;35:1163-9
37. Biancone L, De Nigris F, Del Vecchio Blanco G, et al. Review article: monitoring the activity of Crohns disease. Aliment Pharmacol Ther 2002;16(Suppl 4):29-33
38. DInca R, Di Leo V, Corrao G, et al. Intestinal permeability test as a predictor of clinical course in Crohns disease. Am J Gastroenterol 1999;94:2956-60
39. Beutheu S, Ghouzali I, Galas L, et al. Glutamine and arginine improve permeability and tight junction protein expression in methotrexate-treated Caco- 2 cells. Clin Nutr 2013;32:863-9
40. Barbara G, Stanghellini V, Cremon C, et al. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. Dig Dis 2009; 27(Suppl 1):115-21
41. Leighton MP, Lam C, Mehta S, Spiller RC. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial. Trial 2013;14:10
42. McCormick JB, Hammer RR, Farrell RM, et al. Experiences of patients with chronic gastrointestinal conditions: in their own words. Health Qual Life Outcomes 2012;10:25